Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.73 USD | +4.37% | +3.65% | +85.94% |
Mar. 25 | Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell | MT |
Mar. 25 | Dyne Therapeutics, Inc. Announces Management Changes | CI |
Business Summary
Number of employees: 141
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jason Rhodes
FOU | Founder | 54 | 17-11-30 |
Rick Scalzo
DFI | Director of Finance/CFO | 38 | 19-11-30 |
John Najim
CTO | Chief Tech/Sci/R&D Officer | 48 | 19-07-31 |
Chief Tech/Sci/R&D Officer | 63 | 20-01-26 | |
Chief Tech/Sci/R&D Officer | 61 | 19-06-27 | |
Wildon Farwell
CTO | Chief Tech/Sci/R&D Officer | 49 | 21-03-03 |
Ashish Dugar
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-07 |
Susanna High
COO | Chief Operating Officer | 56 | 20-06-30 |
Amy Reilly
IRC | Investor Relations Contact | 51 | 20-06-30 |
Daniel Wilson
LAW | General Counsel | 53 | 20-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Edward Hurwitz
BRD | Director/Board Member | 60 | 18-10-31 |
David Lubner
BRD | Director/Board Member | 60 | 20-02-29 |
Dirk Kersten
BRD | Director/Board Member | 49 | 18-10-31 |
Jason Rhodes
FOU | Founder | 54 | 17-11-30 |
Carlo Incerti
BRD | Director/Board Member | 65 | 22-03-01 |
Chief Tech/Sci/R&D Officer | 61 | 19-06-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 86,177,719 | 85,700,570 ( 99.45 %) | 0 | 99.45 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+85.94% | 2.13B | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- DYN Stock
- Company Dyne Therapeutics, Inc.